Immune-based therapies for hepatocellular carcinoma

David J. Pinato; Nadia Guerra; Petros Fessas; Ravindhi Murphy; Takashi Mineo; Francesco A. Mauri; Sujit K. Mukherjee; Mark Thursz; Ching Ngar Wong; Rohini Sharma; Lorenza Rimassa

doi:10.1038/s41388-020-1249-9

Immune-based therapies for hepatocellular carcinoma

David J. Pinato, Nadia Guerra, Petros Fessas, Ravindhi Murphy, Takashi Mineo, Francesco A. Mauri, Sujit K. Mukherjee, Mark Thursz, Ching Ngar Wong, Rohini Sharma, Lorenza Rimassa

Risultato della ricerca: Contributo su rivista › Articolo di review › peer review

Abstract

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.

Lingua originale	Inglese
pagine (da-a)	3620-3637
Numero di pagine	18
Rivista	Oncogene
Volume	39
Numero di pubblicazione	18
DOI	https://doi.org/10.1038/s41388-020-1249-9
Stato di pubblicazione	Pubblicato - 30 apr 2020
Pubblicato esternamente	Sì

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1038/s41388-020-1249-9

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{aaba748d5f974d2cb5cae9a28d6b57ad,

title = "Immune-based therapies for hepatocellular carcinoma",

abstract = "Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.",

author = "Pinato, \{David J.\} and Nadia Guerra and Petros Fessas and Ravindhi Murphy and Takashi Mineo and Mauri, \{Francesco A.\} and Mukherjee, \{Sujit K.\} and Mark Thursz and Wong, \{Ching Ngar\} and Rohini Sharma and Lorenza Rimassa",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = apr,

day = "30",

doi = "10.1038/s41388-020-1249-9",

language = "English",

volume = "39",

pages = "3620--3637",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Springer Nature",

number = "18",

}

TY - JOUR

T1 - Immune-based therapies for hepatocellular carcinoma

AU - Pinato, David J.

AU - Guerra, Nadia

AU - Fessas, Petros

AU - Murphy, Ravindhi

AU - Mineo, Takashi

AU - Mauri, Francesco A.

AU - Mukherjee, Sujit K.

AU - Thursz, Mark

AU - Wong, Ching Ngar

AU - Sharma, Rohini

AU - Rimassa, Lorenza

PY - 2020/4/30

Y1 - 2020/4/30

N2 - Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.

AB - Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.

UR - https://www.scopus.com/pages/publications/85081656769

U2 - 10.1038/s41388-020-1249-9

DO - 10.1038/s41388-020-1249-9

M3 - Review article

SN - 0950-9232

VL - 39

SP - 3620

EP - 3637

JO - Oncogene

JF - Oncogene

IS - 18

ER -

Immune-based therapies for hepatocellular carcinoma

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo